Research and Development
We constantly invest in research and development by expanding its portfolio and offering more affordable products to its customers.
Our commitment and pursuit of innovation guide major milestones along our path, such as the launch of Brazil’s first generic oncological product in the early 2000s, and shortly thereafter, generic oral and injectable contraceptives ahead of the competition.
In 2018, we provided the market with the first biosimilar drug in Latin America – Fiprima® (filgrastim). There are only 20 other biosimilar drugs worldwide (19 in Europe and 1 in the United States). The drug is used to induce an increase in the body’s defense cells for patients with some types of cancer, such as breast cancer and leukemia, helping to prevent the emergence of opportunistic infectious diseases.